| Code | CSB-RA015422MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to ALT-100, targeting nicotinamide phosphoribosyltransferase (NAMPT), a rate-limiting enzyme in the NAD+ salvage pathway. NAMPT catalyzes the conversion of nicotinamide to nicotinamide mononucleotide, playing a critical role in cellular energy metabolism, DNA repair, and cell survival. This enzyme exists in both intracellular (iNAMPT) and extracellular (eNAMPT) forms, with the latter functioning as a cytokine-like molecule involved in inflammatory responses and metabolic regulation. Elevated NAMPT expression has been associated with various cancers, metabolic disorders, inflammatory diseases, and aging-related pathologies, making it an important therapeutic target and biomarker.
ALT-100 represents a reference antibody that has been utilized in preclinical and clinical investigations exploring NAMPT inhibition as a therapeutic strategy. This biosimilar provides researchers with a reliable tool for investigating NAMPT biology, validating its role in disease pathogenesis, and supporting drug discovery efforts targeting NAD+ metabolism. The antibody facilitates studies examining NAMPT-dependent cellular processes and therapeutic intervention strategies.
There are currently no reviews for this product.